Skip to main content
Premium Trial:

Request an Annual Quote

Helicos Updates Estimated Restructuring Costs

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Helicos BioSciences today provided an updated estimate of the costs it expects to incur as a result of its restructuring program announced in May.

The Cambridge, Mass.-based maker of a single-molecule sequencing platform said that it expects restructuring costs to total approximately $667,000, of which around $583,000 will relate to employee severance benefits and $84,000 attributed to facility consolidation expenses. That amount is up from its earlier restructuring-cost estimate of between $550,000 and $650,000.

The restructuring included laying off half of its workforce, or 40 positions.

The initial filing with the US Securities and Exchange Commission on May 17 said that the firm expected to report these charges beginning in the second fiscal quarter of 2010 and continuing through the first fiscal quarter of 2011. Helicos did not say in the filing today whether that schedule remains on track.

The firm has not yet reported its second-quarter financial results.

Helicos is in the process of transitioning its focus from the genomics research market to the molecular diagnostics field. In June, the firm said that it intends to commercialize its first sequencing-based test to the market next year.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.